Clinical Trial

Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix

Study acronym: HIVGP-BCG
Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients 1. Treat Infection of Multiple Gene Mutation HIV Virus Strains. 2. Activate Human Antigen Presentation Reaction to HIV Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process HIV target antigen protein into small peptide fragments, and then HIV virus can be killed by APCs directly.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-12.
Trial Details
NCT Number NCT07182838
Lead Sponsor Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Collaborators: UnitedHealthcare
Conditions HIV Infections
Enrollment 20 participants
Start Date 2025-09-12
Primary Completion 2026-08-18 (estimated)
Study Completion 2026-10-28 (estimated)
Updated on ClinicalTrials.gov 2025-10-07